UK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the companys US business development and for establishing a team in the US.
Heading the second Cambridge site
AppointmentsUK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the companys US business development and for establishing a team in the US.
TxCell licenses CAR-T tech
Latest NewsTxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Sciences tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.
Serial founder
AppointmentsManchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015.
Cat allergy setback for Circassia
Latest NewsCircassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The companys shares, listed in London, plunged to a third of its previous value.
Generics visionary
AppointmentsAfter replacing several management positions over the last year, Polands leading generics producer Polpharma now also has a new head. Markus Sieger has succeeded Maurice Chagnaud as President of the Management Board and CEO.
Across the blood-brain barrier with ultrasound
Latest NewsCarTheras ultrasound device opens a gate for therapeutic molecules into the brain, study shows.
Pharma finance pro
AppointmentsResearch service provider Envigo has appointed Patricia Henahan as Chief Financial Officer. She has held similar roles at Eli Lilly, AstraZeneca, Medimmune and Hospira.
Novartis to develop new antimalarial
Latest NewsWith support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.
Humanized NSG and NSG-SGM3 mice as a new preclinical bridge for immune-oncology therapies.
Sponsored PublicationsGilde closes €250m growth fund
Latest NewsEuropean specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.